Article type: Original Article

Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression

Jiesuck Park,[a,b†] Jiyeon Kim,[c†] Yeonyee E. Yoon,[a,b,c*] Jaeik Jeon,[c] Seung-Ah Lee,[c,d] Hong-Mi Choi,[a,b] In-Chang Hwang,[a,b] Goo-Yeong Cho,[a,b] Hyuk-Jae Chang[c,d,e], Jae-Hyeong Park[f*]

[a]Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea

[b]Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

[c]Ontact Health Inc., Seoul, Republic of Korea

[d]CONNECT-AI Research Center, Yonsei University College of Medicine, Seoul, Republic of Korea

[e]Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Republic of Korea

[f]Department of Cardiology, Internal Medicine, Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu Daejeon, 35015, Republic of Korea

[†]The first two authors contributed equally to this work.

Running title: AI for Aortic Stenosis Progression

***Corresponding authors:**

Yeonyee E. Yoon, MD, PhD

Professor, Division of Cardiology, Cardiovascular Center

Seoul National University Bundang Hospital

82, 173 Beon-gil, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

Phone: 82-31-787-7072

Email: yeonyeeyoon@snubh.org

And

Jae-Hyeong Park, MD, PhD

Department of Cardiology, Internal Medicine,

Chungnam National University Hospital,

282 Munhwa-ro, Jung-gu Daejeon, 35015, Republic of Korea

E-mail: jaehyeongpark@gmail.com

ABSTRACT

Aims Aortic stenosis (AS) is a progressive disease requiring timely monitoring and intervention. While transthoracic echocardiography (TTE) remains the diagnostic standard, deep learning (DL)-based approaches offer potential for improved disease tracking. This study examined the longitudinal changes in a previously developed DL-derived index for AS continuum (DLi-ASc) and assessed its value in predicting progression to severe AS.

Methods and Results We retrospectively analysed 2,373 patients a(7,371 TTEs) from two tertiary hospitals. DLi-ASc (scaled 0-100), derived from parasternal long- and/or short-axis views, was tracked longitudinally. DLi-ASc increased in parallel with worsening AS stages (p for trend <0.001) and showed strong correlations with AV maximal velocity (V_{max}) (Pearson correlation coefficients [PCC] = 0.69, p<0.001) and mean pressure gradient (mPG) (PCC = 0.66, p<0.001). Higher baseline DLi-ASc was associated with a faster AS progression rate (p for trend <0.001). Additionally, the annualised change in DLi-ASc, estimated using linear mixed-effect models, correlated strongly with the annualised progression of AV V_{max} (PCC = 0.71, p<0.001) and mPG (PCC = 0.68, p<0.001). In Fine-Gray competing risk models, baseline DLi-ASc independently predicted progression to severe AS, even after adjustment for AV V_{max} or mPG (hazard ratio per 10-point increase = 2.38 and 2.80, respectively)

Conclusion DLi-ASc increased in parallel with AS progression and independently predicted severe AS progression. These findings support its role as a non-invasive imaging-based digital marker for longitudinal AS monitoring and risk stratification.

Keywords: Aortic stenosis; artificial intelligence; echocardiography; progression

1. INTRODUCTION

Aortic stenosis (AS) is a progressive disease that worsens over time and is increasingly prevalent in aging populations.[1,2] Effective management requires timely monitoring and intervention. Transthoracic echocardiography (TTE) remains the gold standard for AS evaluation,[3,4] but its reliance on multiple Doppler-derived parameters introduces variability and requires operator expertise for accurate image acquisition and interpretation. To enhance objectivity and scalability, artificial intelligence (AI) has been explored for AS assessment, primarily in two directions: (1) automating conventional AS evaluation and (2) predicting significant or severe AS using limited imaging data.[5-8]

In this context, we previously developed a novel deep learning (DL)-derived index for the AS continuum (DLi-ASc) that can quantify AS severity using limited TTE views – either parasternal long-axis (PLAX) or parasternal short-axis (PSAX) views.[5] Rigorous validation demonstrated its diagnostic accuracy and prognostic value, comparable to conventional AS parameters. However, its potential utility in predicting AS progression remains unexamined. We hypothesise that this DLi-ASc can facilitate not only the initial assessment of AS but also longitudinal follow-up, aiding in disease monitoring and potentially predicting progression rate.

This study aimed to evaluate temporal changes in the DLi-ASc in relation to AS progression using a longitudinal echocardiographic dataset. Specifically, we examined the temporal trajectory of DLi-ASc across different AS severity stages and its association with conventional echocardiographic parameters. Additionally, we assessed whether baseline DLi-ASc could stratify the risk of rapid progression to severe AS, providing a potential DL-based digital marker for risk prediction and clinical decision-making.

2. METHODS

2.1. Study Population

The study population was collected from two tertiary institutions in South Korea: Seoul National University Bundang Hospital (SNUBH, March 2006 to October 2024) and Chungnam National University Hospital (CNUH, February 2010 to October 2024). Patients who underwent at least two serial TTE examinations and were diagnosed with AS, either at the time of the initial TTE or during follow-up, were included. A total of 2,806 patients with 8,663 TTE examinations were initially identified (SNUBH: 1,639 patients, 5,049 TTEs; CNUH: 1,167 patients, 3,614 TTEs) To ensure the methodological consistency and reliability of AS severity assessment, the following exclusion criteria were applied based on baseline TTE findings: 1) severe AS, 2) ≥ moderate aortic regurgitation, 3) ≥ moderate mitral stenosis or regurgitation, 4) discordant AS classification, defined as cases where aortic valve (AV) maximal velocity (V_{max}), mean pressure gradient (mPG), and AV area (AVA) fell into different severity categories (**Figure 1**). After applying these exclusion criteria, 2,373 patients with 7,371 TTE examinations remained for analysis. This study was approved by the institutional review boards of the participating hospitals, with a waiver for informed consent due to its retrospective, observational design (SNUBH B-2302-808-101; CNUH 2024-11-019). The study adhered to the revision of the Declaration of Helsinki (2013).

2.2. Clinical and Echocardiographic Data Acquisition

All TTE examinations were performed by trained echocardiographers or cardiologists following contemporary guidelines[3,4] and interpreted by board-certified cardiologists who specialised in echocardiography. AV sclerosis was defined as focal or diffuse thickening and calcification with V_{max} <2.0 m/sec and preserved leaflet motion. For follow-up TTEs, when

parameter discordance between Vmax, mPG, and AVA was observed, AS severity was determined based on the final interpretation documented by the attending cardiologist. In cases with indeterminate severity or potential low-flow states, if additional studies, such as dobutamine stress TTE or CT-based AV calcium scoring, had been performed, the results were reviewed and incorporated into the final clinical interpretation. All available TTE examinations for each patient were collected, for those who underwent AV replacement during the follow-up period, only TTE data obtained before the procedure were included. AS severity metrics from each TTE were extracted from clinical reports used for the treatment decision-making.[3]

2.3. DL-Based AS Assessment Algorithm

The DL model used in this study has been previously described and is integrated into an AI-enhanced AS evaluation system (USfeat_valve.ai, Ontact Health, Korea).[5] Briefly, the model utilises a 3-dimensional (3D) convolutional neural network (r2plus1d18) to analyse TTE videos, generating a continuous severity score, the DLi-ASc (range 0–100). This index quantifies AS severity based on limited TTE views - specifically the PLAX and PSAX views at the aortic valve (AV) level. To enhance the reliability of AS severity evaluation, the model incorporates ordered label mapping and multi-task learning, leveraging auxiliary tasks to predict key TTE parameters such as AV maximal velocity (V_{max}), mean pressure gradient (mPG), and AV area (AVA). For each patient, if multiple PLAX or PSAX views were available, DLi-ASc was first averaged within each view type (PLAX and PSAX separately) and then averaged across both views. If only one view type was available, its score was used. The DLi-ASc was generated for all baseline and follow-up TTE examinations included in this study. The DL model successfully generated DLi-ASc for all cases, ensuring full data availability for longitudinal analysis with no exclusions due to model processing failure.

2.4. Statistical Analysis

All statistical analyses were conducted in both the full cohort and the training-excluded cohort, which excluded all patients whose TTE examinations were used in the training phase of the DLi-ASc model[5] (**Figure 1**). This parallel analytical approach was implemented to ensure the robustness and generalizability of our findings, while addressing concerns regarding potential data leakage and overfitting.[9]

Clinical data are described in the study as the median with interquartile range (IQR) or mean with 95% confidence interval (CI) for continuous variables and as percentage numbers for factorial variables. Baseline characteristics were compared between the cohorts, with significant differences determined using the Kruskal-Wallis test and Chi-square test, as appropriate.

The temporal progression of AS severity was illustrated using a proportional stacked bar plot, showing the relative distribution of AS stage (normal AV, AV sclerosis, mild AS, moderate AS, and severe AS) over the follow-up period. This trend was further stratified according to baseline AS severity categories. To assess the significance of ordinal changes in AS stage over time, we employed a Cumulative Link Mixed Model, which accounts for repeated measurements and varying intervals between TTEs.[10] The temporal changes of DLi-ASc were visualised using ridge density plots and analysed using a Linear Mixed Model (LMM), adjusting for repeated TTE measurements and irregular follow-up intervals.[11] The same modelling approach was applied to AV V_{max} and AV mPG, enabling estimation of annual progression rates based on all available serial measurements.

The relationships between DLi-ASc and conventional AS parameters (AV V_{max} and mPG) were evaluated using scatterplots with Pearson correlation coefficients (PCC). To assess the predictive performance of baseline DLi-ASc for AS progression rate, we stratified patients by baseline DLi-ASc categories (<25, 25 to <50, 50 to <75, and ≥75) and compared the

annualised progression rate of V_{max} and mPG across groups. These trends were visualised using violin plots and tested for significance using linear trend analysis. In addition, the associations between the estimated annualised progression rate of DLi-ASc, V_{max}, and mPG – each estimated using LMMs - were also evaluated using scatterplots with PCC.

We assessed the predictive performance of baseline DLi-ASc for progression to severe AS. The earliest TTE demonstrating severe AS was designated as the event date, while patients who did not progress to severe AS were censored at their last available TTE. A competing risk analysis was performed using a Fine and Gray subdistribution hazard model.[12] Two types of competing events were considered: (1) death occurring before the patient fulfilled echocardiographic criteria for severe AS, and (2) AV replacement (AVR) performed for other indication prior to meeting those criteria. The proportional hazards assumption was tested and confirmed to be satisfied. DLi-ASc was evaluated both as a continuous variable (per 10-point increase) and as a categorical variable using predefined score groups: <50, 50 to <60, 60 to <70, and ≥70. To test the robustness of its prognostic value, three adjustment strategies were employed: (1) clinical factors only (age, sex, and estimated glomerular filtration rate [eGFR]), (2) clinical factors plus AV V_{max}, and (3) clinical factors plus AV mPG. Subdistribution hazard ratios (HRs) with 95% confidence intervals (CIs) were reported for both continuous and categorical models. In addition, to exclude pre-diagnostic variability and validate the predictive performance of DLi-ASc in a clinically confirmed AS population, we conducted a sensitivity analysis restricted to patients whose baseline TTE corresponded to the first examination at which AS was clinically diagnosed. The Fine and Gray competing risk model was reapplied in this subset using the same adjustment strategies to ensure consistency with the primary analysis.

All statistical analyses were performed using R software (v4.5.0; R Development Core Team, Vienna, Austria). Two-sided p-values <0.05 were considered statistically significant.

2.5. Funding

The study was supported by a grant from the Institute of Information & communications Technology Planning & Evaluation (IITP) funded by the Korea government (Ministry of Science and ICT); and the Medical AI Clinic Program through the NIPA funded by the MSIT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

3. RESULTS

3.1. Baseline Characteristics

A total of 2,373 patients with 7,371 TTE examinations were included in the full analysis cohort. The training-excluded cohort, consisting of patients with no overlap with the DLi-ASc training dataset, comprised 1,117 patients and 3,376 TTEs (**Figure 1**). The median age was 76 years (interquartile range [IQR] 69–82) in the full cohort and 75 years (IQR 68-81) in the training-excluded cohort, with a similar sex distribution (**Table 1).** Baseline AS severity in the full cohort included normal AV (8.4%), AV sclerosis (18.9%), mild AS (53.2%), and moderate AS (19.4%). In the training-excluded cohort, the distribution shifted toward earlier disease stages, with a higher proportion of normal AV (17.6%) and AV sclerosis (26.9%), and a lower proportion of mild AS (34.6%). Median baseline DLi-ASc values were similar between the two groups: 49 (IQR 46–52) in the full cohort and 49 (IQR 45–52) in the training-excluded cohort. Median follow-up duration was slightly longer in the training-excluded cohort (47.8 months vs. 42.8 months), though the median number of follow-up TTEs was comparable (3 [IQR 2–4] vs. 3 [IQR 2–3]). Comparative baseline characteristics stratified by institution (SNUBH vs. CNUH) are presented in **Supplemental Result 1**.

3.2. Temporal Changes in AS Severity and Corresponding DLi-ASc Distributions

The median follow-up duration from baseline TTE was 42.8 months (IQR 22.2–75.7 months) in the full cohort and 47.8 months (IQR 21.0-87.8 months) in the training-excluded cohort. As shown in **Figure 2**, the distribution of AS stages demonstrated a progressive shift toward more advanced stages over time in both cohorts, with increasing proportions of moderate and severe AS as the follow-up period extended (p for trend <0.001, based on cumulative link mixed model). This trend was consistently observed across all baseline AS severity categories (all p

for trend < 0.001; **Supplemental Result 2**). Longitudinal trends of conventional AS parameters were examined using LMM. Annualised progression rates were 0.06 m/s/year (95% CI, 0.05–0.10) for V_{max} and 0.67 mmHg/year (95% CI, 0.34–1.34) for mPG in the full cohort, and 0.07 m/s/year (95% CI, 0.05–0.10) and 0.83 mmHg/year (95% CI, 0.50–1.44), respectively, in the training-excluded cohort (**Supplemental Result 3**).

In parallel, DLi-ASc also increased longitudinally across all baseline AS severity categories. As illustrated in **Figure 3**, the density distributions of DLi-ASc shifted progressively toward higher values over follow-up years, with all trends statistically significant (p for trend <0.001). Corresponding median DLi-ASc values at baseline and follow-up are summarised in **Supplemental Result 4**. For example, in the full cohort, DLi-ASc increased from 44 to 49 in normal AV, from 48 to 50 in AV sclerosis, from 49 to 53 in mild AS, and from 56 to 63 in moderate AS over 6 years. These patterns were also observed in the training-excluded cohort. The annualised rate of DLi-ASc progression was 1.11 (95% CI, 1.03-1.55) in the full cohort and 1.11 (95% CI, 1.02-1.23) in the training-excluded cohort, with progressively higher rates observed across worsening baseline severity categories (all p for trend <0.001; **Supplemental Result 3**).

For complementary visualisation of individual-level DLi-ASc trajectories, subject-level connected line plots are also provided (**Supplemental Results 5**). These findings align with **Figure 3**, reinforcing DLi-ASc's potential as a surrogate marker for monitoring long-term AS progression. While DLi-ASc generally increased over time, transient decreases were observed in 33.9% of consecutive TTE pairs, mostly when the follow-up interval was short (median 13 months). When comparing only the first and last TTEs (median 43 months), the proportion showing a net decrease dropped to 23.2%, again predominantly in cases with shorter follow-up. Notably, the absolute magnitude of DLi-ASc change increased with longer interscan intervals (**Supplemental Results 6**), suggesting that short-term decreases are more likely due

to technical or image-related variability than true biological improvement.

3.3 Association of DLi-ASc with AS Severity and Progression

Analysis of all TTE examinations during follow-up revealed a significant positive correlation between DLi-ASc and conventional AS parameters in both the full and training-excluded cohorts, indicating that higher DLi-ASc values reflect greater hemodynamic severity. In the full cohort, PCC was 0.69 (95% CI: 0.67–0.70, p<0.001) for AV V_{max} and 0.66 (95% CI: 0.65-0.68, p<0.001) for AV mPG; in the training-excluded cohort, the corresponding values were 0.67 (95% CI: 0.65-0.69, p<0.001) and 0.61 (95% CI: 0.59-0.63, p<0.001), respectively (**Figure 4**).

Furthermore, stratification by baseline DLi-ASc categories revealed significant positive trends, with higher baseline DLi-ASc associated with faster progression of both AV V_{max} and mPG (all p for trend <0.001) (**Figure 5**). In addition, annualised progression parameters derived from LMMs (**Supplemental Results 7**) showed strong positive correlations between changes in DLi-ASc and corresponding change in AV V_{max} (PCC = 0.71, 95% CI: 0.69–0.73, p < 0.001) and mPG (PCC = 0.68, 95% CI: 0.66–0.70, p < 0.001). The training-excluded cohort demonstrated consistent results, with PCC of 0.72 (95% CI: 0.69-0.74, p<0.001) for V_{max} and 0.66 (95% CI: 0.63-0.69, p<0.001) for mPG. These findings suggest that both the baseline level and longitudinal increase in DLi-ASc are closely aligned with the hemodynamic progression of AS.

3.4. Predictive Performance of DLi-ASc of Severe AS Progression

Cumulative incidence curves accounting for death and AVR as a competing risk demonstrated a gradual increase in the risk severe AS progression across higher baseline DLi-ASc categories

in both full and training-excluded cohorts (**Figure 6**). Notably, patients with baseline DLi-ASc ≥ 60 consistently showed greater cumulative incidence than those with lower DLi-ASc, the curves for the 60-70 and ≥70 groups appeared largely comparable over time.

To further evaluate the independent prognostic value of DLi-ASc, we applied Fine and Gray competing risk model using three adjustment strategy: (1) clinical factors only (age, sex, and eGFR), (2) clinical factors plus AV V_{max}, (3) clinical factors plus AV mPG. In full cohort, baseline DLi-ASc remained a significant predictor under all models (**Table 2**). The adjusted HR per 10-point increase was 4.03 (95% CI: 3.40-4.78) with clinical factors only, 2.41 (95% CI: 2.09-2.78) after additional adjustment for AV V_{max}, and 2.81 (95% CI: 2.41-3.29) after adjustment for mPG. Categorical DLi-ASc groups were also significantly associated with increased risk compared to the <50 reference group. For example, in the V_{max}-adjusted model, DLi-ASc of 60–70 and ≥70 were associated with HRs of 4.59 (95% CI: 2.37–8.89) and 10.80 (95% CI: 5.60–20.81), respectively. In the training-excluded cohort, the adjusted HR per 10-point increase in DLi-ASc was 3.21 (95% CI: 2.65–3.89) with clinical factors only, 2.19 (95% CI: 1.82–2.62) with V_{max} adjustment, and 2.53 (95% CI: 2.08–3.07) with mPG adjustment. Consistent findings were observed for categorical DLi-ASc groups.

To validate the predictive performance of DLi-ASc in a clinically confirmed AS population, we performed a sensitivity analysis excluding pre-diagnosis TTEs, defining baseline as the first exam at which AS was diagnosed (**Supplemental Result 8**). In this subset, DLi-ASc remained independently associated with severe AS progression across all adjustment models. For example, in the full cohort, the adjusted HR per 10-point increase was 1.87 (95% CI: 1.80–2.18) after AV V_{max} adjustment and 2.13 (95% CI: 1.80–2.50) after AV mPG adjustment. Similar associations were observed in the training-excluded cohort. These findings confirm the robustness of DLi-ASc as a prognostic marker even when restricted to post-diagnosis follow-up.

4. DISCUSSION

In this study, we further evaluated the clinical utility of DLi-ASc, a DL-derived quantitative AS severity metric initially developed for cross-sectional assessment. Leveraging a large, longitudinal dataset, we demonstrated its potential for tracking AS progression over time. Notably, our analysis included TTE examinations obtained prior to clinical AS diagnosis, enabling DLi-ASc to capture disease evolution across the full spectrum – from normal AV to advanced stenosis. DLi-ASc increased in parallel with AS severity over time and remained strongly correlated with conventional hemodynamic markers such as AV V_{max} and mPG when pooled across all timepoints. Importantly, we also found that both baseline DLi-ASc and its rate of increase were significantly associated with the progression of AV V_{max} and mPG, suggesting that DLi-ASc reflects not only cross-sectional severity but also longitudinal hemodynamic deterioration. Furthermore, baseline DLi-ASc independently predicted progression to severe AS, even after adjustment for AV V_{max} or mPG, supporting its value as a robust and continuous marker of disease trajectory.

The role of AI in TTE is evolving. Early applications focused on automating manual measurements, enhancing accuracy and reproducibility. With most TTE parameters now capable of automation, AI has expanded to disease severity assessment, as seen in diastolic dysfunction[13,14] and AS evaluation.[8] More recently, AI has progressed beyond parameter-based analysis to DL-based direct TTE video analysis, aiming to mimic expert visual assessment.[5-7,13] In our previous study, we developed a DL model capable of accurately assessing AS severity using PLAX and/or PSAX views.[5] The strength of this DL-based index lies in its ability to mimic visual analysis while providing a quantitative digital marker. Our prior work validated this approach in a large cross-sectional cohort, confirming its diagnostic performance. However, while the model was designed to reflect the AS disease continuum, whether DLi-ASc would increase in parallel with AS progression over time remained unclear.

While previous studies have introduced DL-based indices for assessing AS,[5-7] this study is the first to validate a progressive increase in a DL-derived AS marker over serial follow-up examinations, underscoring the utility of DLi-ASc for longitudinal AS monitoring. Oikonomou et al. developed the Digital AS Severity Index (DASSi), PLAX view-based DL metric designed to predict severe AS,[6] and reported its potential prognostic value.[15] However, their study did not evaluate whether the DL index itself increased over time in parallel with AS progression. In contrast, our analysis uniquely showed that DLi-ASc consistently increased over time, closely mirroring the natural course of AS. Moreover, this longitudinal increase was evident not only in patients progressing to severe AS but also in those transitioning from normal AV function to subclinical or early stage disease, suggesting that DLi-ASc may detect early pathological changes before overt clinical diagnosis. Supporting this, baseline DLi-ASc values in patients with normal AV or AV sclerosis were higher than those reported in our prior study, [5] likely reflecting early pathological changes. Unlike the prior cohort, which included individuals without AS, the current study enrolled patients who eventually developed AS during follow-up, thereby capturing the earliest phases of disease evolution. By utilising a large longitudinal cohort, this study bridges an important gap, positioning DLi-ASc not only as a marker for AS detection but also as a robust tool for tracking disease progression over time. This unique capability supports its potential use in risk stratification and longitudinal monitoring, laying the groundwork for integrating DL-based metrics into routine clinical practice. Nonetheless, further studies are needed to validate its clinical applicability and define its role within standardised clinical pathways.

Furthermore, this study demonstrated that DLi-ASc is associated with AS progression rate and serves as an independent predictor of severe AS progression risk. While AVA, V_{max}, and mPG remain the gold standard for AS severity assessment, DLi-ASc offers a continuous, DL-driven risk metric that complements existing markers and enables quantitative risk

stratification. The cumulative incidence analysis revealed clear stratification by DLi-ASc categories, particularly among patients with scores ≥60, who exhibited significantly higher event rates. This reinforces the potential utility of DLi-ASc in guiding personalised surveillance strategies. Rather than applying uniform monitoring intervals to all AS patients, tailoring follow-up frequency based on DLi-ASc may allow for earlier detection rapid progression. In addition, although current AS management primarily focuses on AV replacement after severe AS develops, the ability to quantify AS progression with DLi-ASc could become particularly valuable if medical treatment to slow AS progression becomes available in the future. In such a scenario, DLi-ASc could serve as a quantitative marker for tracking disease progression and identifying patients at higher risk for rapid progression who may benefit from earlier or more aggressive intervention. Despite its promise, clinical implementation of AI-based tools like DLi-ASc may be influenced by factors such as accessibility, cost, and integration into existing echocardiographic workflows. Future efforts should focus on optimising deployment strategies to ensure widespread clinical applicability.

This study has several limitations. First, the retrospective nature of data collection introduces inherent constraints. Although commonly used,[15,16] progression tracking relied primarily on flow-dependent metrics such as V_{max} and mPG, which are susceptible to variations in stroke volume and hemodynamic loading conditions. However, diagnosis of severe AS was not based solely on these parameters, but rather on comprehensive clinical interpretation that incorporated flow status documented in TTE reports and, when available, results from additional diagnostic tests. In addition, TTE intervals were not standardised, limiting the precision of annual progression estimates based on either based on conventional AS parameters or DLi-ASc. To address this, we employed LMMs, which account for repeated measures and variable follow-up intervals. This approach utilises longitudinal TTE data and patient-level trajectory modelling, thereby reducing bias from irregular TTE schedules and improving the

robustness of the estimated progression rate. For sure, future prospective studies with standardised follow-up protocols – incorporating both flow-dependent and flow-independent measures such as CT-based AV calcium scoring – could further validate the value of DLi-ASc in assessing the temporal dynamics of AS progression in a more systematic manner and may also enable advanced modelling approaches – such as trajectory clustering or unsupervised pattern recognition – to explore distinct AS progression phenotypes. Furthermore, although coronary artery disease (CAD) is a major competing risk in patients with mild to moderate AS, CAD-specific diagnostic or outcome data were not uniformly available due to the retrospective design. To mitigate potential bias, we applied a Fine and Gray competing risk model treating death as a competing event. Still, the lack of adjudicated CAD outcomes remains a limitation, and future studies should incorporate comprehensive ischemic event data to further evaluate the prognostic value of DLi-ASc. Second, the dataset was derived from two tertiary hospitals in South Korea, where TTE examinations were performed by specialised cardiologists with expertise in echocardiography. While this ensures high-quality imaging and reliable data, it also raises concerns about generalizability to resource-limited settings, where non-experts often perform TTE. Since DLi-ASc was developed to enhance AS assessment across diverse clinical environments, further studies are needed to evaluate its performance in settings with limited echocardiographic expertise. Additionally, while DL analysis was successfully performed in all cases and DLi-ASc generally increased over time, transient decreases were occasionally observed, particularly with short follow-up intervals. These likely reflect technical or image-related variability, representing an inherent limitation of DL-based image analysis. Finally, to ensure broader generalizability, additional research in diverse racial and geographic populations is essential to establish the clinical applicability and real-world implications of DLi-ASc.

5. CONCLUSION

This study demonstrated the utility of DLi-ASc for longitudinal monitoring and risk stratification in AS. DLi-ASc increased progressively in line with disease severity and was significantly associated with conventional hemodynamic parameters such as AV V_{max} and mPG. Importantly, higher baseline DLi-ASc independently predicted future progression to severe AS, even after adjustment for conventional hemodynamic markers. These findings support the potential of DLi-ASc as a noninvasive imaging biomarker for tracking disease trajectory and identifying high-risk patients for rapid progression.

Contributors

All authors contributed equally to this study. All authors have read and approved the final version of the manuscript. J.P, J.K, and Y.E.Y verified the underlying data of the current study.

Data Sharing Statement

Please contact the corresponding author (yeonyeeyoon@gmail.com) to request the minimal anonymised dataset. Researchers with additional inquiries about the deep learning model developed in this study are also encouraged to reach out to the corresponding author.

Declaration of Interests

Y.E.Y, J.J., J.K., and S.A.L. are currently affiliated with Ontact Health, Inc. J.J., J.K., and S.A.L are co-inventors on a patent related to this work filed by Ontact Health (Method For Providing Information On Severity Of Aortic Stenosis And Device Using The Same). H.J.C., and Y.E.Y hold stock in Ontact Health, Inc. The other authors have no conflicts of interest to declare.

Acknowledgements

This work was supported by a grant from the Institute of Information & communications Technology Planning & Evaluation (IITP) funded by the Korea government (Ministry of Science and ICT) (No.2022000972, Development of a Flexible Mobile Healthcare Software Platform Using 5G MEC); and the Medical AI Clinic Program through the NIPA funded by the MSIT. (Grant No.: H0904-24-1002).

REFERENCES

1 Owens DS, Bartz TM, Buzkova P, Massera D, Biggs ML, Carlson SD, et al. Cumulative burden of clinically significant aortic stenosis in community-dwelling older adults. *Heart*. 2021;107:1493–1502.

2 Yi B, Zeng W, Lv L, Hua P. Changing epidemiology of calcific aortic valve disease: 30-year trends of incidence, prevalence, and deaths across 204 countries and territories. *Aging*. 2021;13:12710–12732.

3 Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2021;77:e25–e197.

4 Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, et al. Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2017;30:372–392.

5 Park J, Kim J, Jeon J, Yoon YE, Jang Y, Jeong H, et al. Artificial intelligence-enhanced comprehensive assessment of the aortic valve stenosis continuum in echocardiography. *EBioMedicine*. 2025;112:105560.

6 Holste G, Oikonomou EK, Mortazavi BJ, Coppi A, Faridi KF, Miller EJ, et al. Severe aortic stenosis detection by deep learning applied to echocardiography. *Eur Heart J*. 2023;44:4592–4604.

7 Wessler BS, Huang Z, Long GM Jr, Pacifici S, Prashar N, Karmiy S, et al. Automated Detection of Aortic Stenosis Using Machine Learning. *J Am Soc Echocardiogr*. 2023;36:411–420.

8 Krishna H, Desai K, Slostad B, Bhayani S, Arnold JH, Ouwerkerk W, et al. Fully

Automated Artificial Intelligence Assessment of Aortic Stenosis by Echocardiography. *J Am Soc Echocardiogr*. 2023;36:769–777.

9 Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *Ann Intern Med*. 2015;162:55–63.

10 Christensen RHB. ordinal-regression models for ordianl data. R-package Version 2023.12-4. The R Foundation. 2023. Retrieved from https://CRAN.R-project.org/package=ordinal.

11 Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software. 2015;67:1–48.

12 Gray B. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-11. The R Foundation. 2024. Retrieved from https://CRAN.R-project.org/package=cmprsk.

13 Chen X, Yang F, Zhang P, Lin X, Wang W, Pu H, et al. Artificial Intelligence-Assisted Left Ventricular Diastolic Function Assessment and Grading: Multiview Versus Single View. *J Am Soc Echocardiogr*. 2023;36:1064–1078.

14 Park J, Jeon J, Yoon YE, Jang Y, Kim J, Jeong D, et al. Artificial intelligence-enhanced automation of left ventricular diastolic assessment: a pilot study for feasibility, diagnostic validation, and outcome prediction. *Cardiovasc Diagn Ther*. 2024;14:352–366.

15 Oikonomou EK, Holste G, Yuan N, Coppi A, McNamara RL, Haynes NA, et al. A Multimodal Video-Based AI Biomarker for Aortic Stenosis Development and Progression. *JAMA Cardiol*. 2024;9:534–544.

16 Willner N, Prosperi-Porta G, Lau L, Nam Fu AY, Boczar K, Poulin A, et al. Aortic Stenosis Progression: A Systematic Review and Meta-Analysis. *JACC Cardiovasc Imaging*. 2023;16:314–328.

Table 1. Baseline Characteristics of the Full Cohort and the Training-Excluded Cohort

	Full Cohort (n=2,373)	Training-Excluded Cohort (n=1,117)
Age	76 (69–82)	75 (68–81)
Male	1,093 (46.1)	523 (46.8)
Female	1,280 (53.9)	594 (53.2)
BSA	1.7 (1.5–1.8)	1.6 (1.5–1.8)
Baseline AS Severity		
Normal	200 (8.4)	197 (17.6)
AV Sclerosis	449 (18.9)	301 (26.9)
Mild AS	1,263 (53.2)	386 (34.6)
Moderate AS	461 (19.4)	233 (20.9)
Baseline DLi-ASc	49 (46–52)	49 (45–52)
Follow-up, months	42.8 (22.2–75.7)	47.8 (21.0–87.8)
No. of TTEs	7,371	3,376
No. of TTE FU	3 (2–4)	3 (2–3)
At least 3 exams	1,259 (53.1)	569 (50.9)
At least 4 exams	639 (26.9)	276 (24.7)

Values are given as numbers (percentage) or median (interquartile range).
Abbreviations: AS, aortic valve stenosis; AV, aortic valve; BSA, body surface area; CNUH, Chungnam National University Hospital; DLi-ASc, deep learning-derived index for the AS continuum; FU, follow-up

Table 2. Prognostic Value of Baseline DLi-ASc for Severe AS Progression Under Different Adjustment Strategies

	Unadjusted HR (95% CI)	Adjusted HR (95% CI) (Clinical factors)	Adjusted HR (95% CI) (Clinical factors + AV Vmax)	Adjusted HR (95% CI) (Clinical factors + AV mPG)
Full Cohort				
DLi-ASc, per 10-score increase	3.88 (3.18-4.74)	4.01 (3.38-4.75)	2.38 (2.07-2.76)	2.80 (2.39-3.27)
DLi-ASc <50	reference	reference	reference	reference
DLi-ASc 50 to <60	4.68 (3.81-5.74)	4.86 (3.94-6.00)	3.11 (2.55-3.80)	3.66 (2.98-4.51)
DLi-ASc 60 to <70	24.23 (17.28-33.97)	25.28 (17.96-35.59)	4.53 (2.34-8.77)	7.01 (3.84-12.78)
DLi-ASc 70 ≤	31.82 (15.12-66.93)	33.18 (16.31-67.51)	10.63 (5.51-20.50)	16.13 (8.36-31.12)
Training-Excluded Cohort				
DLi-ASc, per 10-score increase	3.02 (2.40-3.80)	3.16 (2.61-3.83)	2.15 (1.80-2.58)	2.49 (2.05-3.03)
DLi-ASc <50	reference	reference	reference	reference
DLi-ASc 50 to <60	4.73 (3.56-6.29)	4.85 (3.62-6.52)	3.03 (2.30-3.99)	3.54 (2.66-4.73)
DLi-ASc 60 to <70	15.53 (9.79-24.64)	16.06 (10.08-25.57)	3.50 (1.32-9.28)	6.04 (2.52-14.47)
DLi-ASc 70 ≤	19.38 (5.89-63.77)	20.13 (6.41-63.20)	9.38 (3.47-25.36)	13.82 (4.90-38.99)

Clinical factors include age, sex, and estimated glomerular filtration rate (eGFR). Subdistribution HRs were estimated using Fine and Gray competing risk models for severe AS progression.

Abbreviations: AS, aortic valve stenosis; AV, aortic valve; CI, confidence interval; DLi-ASc, deep learning-derived index for the AS continuum; HR, hazard ratio; mPG, mean pressure gradient; Vmax, maximal transvalvular velocity.

Figure 1. Study Population

AS = aortic stenosis, TTE = transthoracic echocardiography



Figure 2. Temporal Progression of AS Severity Over Follow-Up Years

AS = aortic stenosis, AV = aortic valve



Figure 3. Temporal Trends in DLi-ASc Across Baseline AS Severity Categories

AS = aortic stenosis; DLi-ASc = deep learning-derived index for the AS continuum.



Figure 4. Association of DLi-ASc with Conventional Hemodynamic Parameters of AS

See abbreviations in Figure 2.



Figure 5. Baseline DLi-ASc and Its Association with Annualised Changes in AV V_{max} and mPG

See abbreviations in Figure 2. mPG = mean pressure gradient, V_{max} = maximal velocity



Figure 6. Cumulative Incidence of Severe AS Progression Stratified by Baseline DLi-ASc

See abbreviations in Figure 2.